NO20026123L - Farmasöytiske sammensetninger - Google Patents

Farmasöytiske sammensetninger

Info

Publication number
NO20026123L
NO20026123L NO20026123A NO20026123A NO20026123L NO 20026123 L NO20026123 L NO 20026123L NO 20026123 A NO20026123 A NO 20026123A NO 20026123 A NO20026123 A NO 20026123A NO 20026123 L NO20026123 L NO 20026123L
Authority
NO
Norway
Prior art keywords
pharmaceutical compositions
pharmaceutical
compositions
Prior art date
Application number
NO20026123A
Other languages
English (en)
Other versions
NO20026123D0 (no
Inventor
Sabina Maria Ganter
Robert Frank Wagner
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20026123D0 publication Critical patent/NO20026123D0/no
Publication of NO20026123L publication Critical patent/NO20026123L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
NO20026123A 2000-06-22 2002-12-19 Farmasöytiske sammensetninger NO20026123L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59968700A 2000-06-22 2000-06-22
PCT/EP2001/006983 WO2001097805A2 (en) 2000-06-22 2001-06-20 Solid valsartan pharmaceutical compositions

Publications (2)

Publication Number Publication Date
NO20026123D0 NO20026123D0 (no) 2002-12-19
NO20026123L true NO20026123L (no) 2003-02-18

Family

ID=24400655

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20026123A NO20026123L (no) 2000-06-22 2002-12-19 Farmasöytiske sammensetninger

Country Status (21)

Country Link
EP (2) EP2072049A3 (no)
JP (3) JP2003535895A (no)
KR (2) KR100525341B1 (no)
CN (2) CN100450478C (no)
AU (2) AU2001285768B2 (no)
BR (1) BR0111868A (no)
CA (1) CA2411882C (no)
CZ (1) CZ20024180A3 (no)
EC (1) ECSP024389A (no)
HK (2) HK1052868A1 (no)
HU (1) HUP0301390A3 (no)
IL (2) IL153428A0 (no)
MX (1) MXPA02012683A (no)
NO (1) NO20026123L (no)
NZ (2) NZ522953A (no)
PL (1) PL358290A1 (no)
RU (1) RU2333757C2 (no)
SG (1) SG162605A1 (no)
SK (1) SK18062002A3 (no)
WO (1) WO2001097805A2 (no)
ZA (1) ZA200210359B (no)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1588706T1 (sl) * 1998-12-23 2012-01-31 Novartis Ag Tableta valsartana
US7468390B2 (en) 2002-01-17 2008-12-23 Novartis Ag Methods of treatment and pharmaceutical composition
KR20100057704A (ko) * 2002-01-17 2010-05-31 노파르티스 아게 발사르탄 및 ｎｅｐ 저해제를 포함하는 제약학적 조성물
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
TWI299663B (en) * 2002-05-14 2008-08-11 Novartis Ag Methods of treatment
WO2005013964A1 (ja) * 2003-08-08 2005-02-17 Ajinomoto Co., Inc. ナテグリニド含有製剤
WO2006021443A2 (en) * 2004-08-26 2006-03-02 Novartis Ag Composition comprising an at1 receptor blocker and a macrolide t-cell immunomodulator
EP1833464A1 (en) 2004-12-24 2007-09-19 KRKA, tovarna zdravil, d.d., Novo mesto Solid pharmaceutical composition comprising valsartan
JP2009001520A (ja) * 2007-06-21 2009-01-08 Kowa Co ジフェンヒドラミン含有固形製剤
EP2197416A1 (en) 2007-10-09 2010-06-23 Novartis Ag Pharmaceutical formulation of valsartan
WO2009059605A1 (en) * 2007-11-08 2009-05-14 University Of Copenhagen Small scale solid state screening
EP2067470A1 (en) * 2007-12-03 2009-06-10 Laboratorios Lesvi, S.L. Pharmaceutical compositions containing valsartan and process for its preparation
WO2011102702A2 (en) 2010-02-16 2011-08-25 Krka, D. D., Novo Mesto Process for the preparation of oral solid dosage forms comprising valsartan
CN102362865B (zh) * 2011-10-28 2013-06-26 山东司邦得制药有限公司 一种含有盐酸贝尼地平和缬沙坦的复方制剂及其应用
WO2013098576A1 (en) 2011-12-31 2013-07-04 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Immediate release pharmaceutical composition of valsartan
WO2013098578A1 (en) 2011-12-31 2013-07-04 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Immediate release pharmaceutical composition of valsartan hydrochlorothiazide
CN103599084B (zh) * 2013-11-22 2018-10-30 威海迪素制药有限公司 一种降压组合物
CN112826806A (zh) * 2021-01-20 2021-05-25 海南皇隆制药股份有限公司 一种缬沙坦片制备方法和缬沙坦片
CN112807286A (zh) * 2021-01-20 2021-05-18 海南皇隆制药股份有限公司 一种缬沙坦分散片制备方法和缬沙坦分散片
EP4295839A1 (en) 2022-06-20 2023-12-27 KRKA, d.d., Novo mesto Combination of valsartan and indapamide

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE134624T1 (de) 1990-02-19 1996-03-15 Ciba Geigy Ag Acylverbindungen
HUT76542A (en) * 1994-03-17 1997-09-29 Ciba Geigy Ag Use of valsartan for the preparation of pharmaceutical composition serving for the treatment of diabetic nephropathy
PT853477E (pt) * 1995-10-06 2003-01-31 Novartis Ag Antagonistas de receptores at1 para prevencao e tratamento de insuficiencia renal pos-isquemica e para proteccao de rim isquemico
DK0883401T3 (da) * 1996-02-29 2003-05-05 Novartis Ag AT1-receptorantagonist til stimulering af apoptose
IL124935A (en) * 1996-05-20 2001-06-14 Janssen Pharmaceutica Nv Dissolvable fungicidal preparations contain itraconazole with improved bioavailability
GB9613470D0 (en) * 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
US6362371B1 (en) * 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
SE9802973D0 (sv) * 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
SI1588706T1 (sl) * 1998-12-23 2012-01-31 Novartis Ag Tableta valsartana
MXPA02010090A (es) * 2000-04-12 2003-02-12 Novartis Ag Combinacion de al menos dos compuestos seleccionados de los grupos de un antagonista del receptor at-1 o un inhibidor ace o un inhibidor de la hmg-co-a reductasa.

Also Published As

Publication number Publication date
KR20050085978A (ko) 2005-08-29
MXPA02012683A (es) 2003-04-25
ECSP024389A (es) 2003-02-06
AU2001285768B2 (en) 2005-03-10
CN1221256C (zh) 2005-10-05
HK1052868A1 (zh) 2003-10-03
ZA200210359B (en) 2003-11-13
HUP0301390A2 (hu) 2003-11-28
CZ20024180A3 (cs) 2003-04-16
BR0111868A (pt) 2003-07-01
AU8576801A (en) 2002-01-02
NZ522953A (en) 2005-10-28
EP2072049A2 (en) 2009-06-24
HUP0301390A3 (en) 2005-04-28
JP2012211200A (ja) 2012-11-01
KR20030019450A (ko) 2003-03-06
IL153428A0 (en) 2003-07-06
JP2003535895A (ja) 2003-12-02
CA2411882C (en) 2011-09-06
CN1679551A (zh) 2005-10-12
EP2072049A3 (en) 2009-12-30
KR100659644B1 (ko) 2006-12-21
SK18062002A3 (sk) 2003-07-01
PL358290A1 (en) 2004-08-09
NO20026123D0 (no) 2002-12-19
SG162605A1 (en) 2010-07-29
JP2007091758A (ja) 2007-04-12
WO2001097805A2 (en) 2001-12-27
IL153428A (en) 2013-12-31
EP1296677A2 (en) 2003-04-02
NZ540748A (en) 2007-04-27
HK1083452A1 (en) 2006-07-07
CN100450478C (zh) 2009-01-14
RU2333757C2 (ru) 2008-09-20
WO2001097805A3 (en) 2002-08-29
CA2411882A1 (en) 2001-12-27
KR100525341B1 (ko) 2005-11-02
CN1437469A (zh) 2003-08-20

Similar Documents

Publication Publication Date Title
FI20105657A (fi) Farmaseuttisia koostumuksia
AR028204A1 (es) Composiciones farmaceuticas electrohiladas
ITMI20010748A0 (it) Composizioni farmaceutiche
DK1524266T3 (da) Farmaceutisk sammensætning
NO20025450L (no) Ny farmasöytisk sammensetning
ATE303787T1 (de) Schergelzusammensetzungen
ITTO20010008A0 (it) Formulazione farmaceutica
PT1242087E (pt) Composicoes farmaceuticas
FI20011478A0 (fi) Farmaseuttinen koostumus
NO20033556L (no) Farmasöytiske formuleringer
NO20015175D0 (no) Farmasöytisk sammensetning
AR028197A1 (es) Composiciones antitranspirantes
AT7729U3 (de) Pharmazeutische zusammensetzungen enthaltend amlodipinmaleat
EE05020B1 (et) Glburiidi ravimkoostis
EE200300589A (et) Ravimkoostised
NO20026123L (no) Farmasöytiske sammensetninger
ATE369830T1 (de) Schweisshemmende zusammensetzungen
ATE314049T1 (de) Schweisshemmende zusammensetzungen
PT1239832E (pt) Composicoes farmaceuticas
FI20022128A (fi) Farmaseuttinen koostumus
NO20031095D0 (no) Farmasöytiske sammensetninger
DE60116858D1 (de) Zusammensetzung
FI4488U1 (fi) Farmaseuttinen koostumus
EE200200689A (et) Ravimkoostised
MXPA03001857A (es) Composicones medicinales.